Last reviewed · How we verify

NCT05093764

Quantification of Debris Captured Using TCEP During VIV TAVR With BVF

Recruiting now NA Last updated 14 June 2024
What this trial tests

NA trial testing VIV TAVR with BVF using TCEP in Aortic Valve Disease in 20 participants. Currently enrolling.

Timeline
2 March 2022
Primary endpoint
31 December 2024
31 December 2025

Quick facts

Lead sponsorSaint Luke's Health System
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date2 March 2022
Primary completion31 December 2024
Estimated completion31 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Saint Luke's Health System — full company profile →

Who can join

18 and older, any sex, with Aortic Valve Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to quantify the amount of debris captured by the SENTINEL transcatheter cerebral embolic protection (TCEP) device in patients undergoing valve in valve transcatheter aortic valve replacement (VIV TAVR) with bioprosthetic valvular fracture (BVF)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Valve Disease

Currently open trials in the same condition.

Other Saint Luke's Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05093764.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing